All In Biotech

Drug Trial Radar · NCT05701241

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients - The SAUNA Trial

Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Jun 28, 2023

Primary completion

Apr 2029

Study completion Apr 2034

Sponsor

Lead sponsor
University Hospital, AntwerpAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research and Development; Belgium Health Care Knowledge Centre
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy. Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumor

Interventions

  • Somatostatin analogDrug

    Somatostatin analog treatment every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudyTime frame: 18 months after start second-line treatment
  2. The difference in time to deterioration (TTD) in patients continuing or stopping second-line therapy with SSAs per substudyTime frame: 18 months after start second-line treatment

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • AZ Monica

    Antwerp, Belgium · Not yet recruiting

  • GZA

    Antwerp, Belgium · Active not recruiting

  • Ziekenhuis Netwerk Antwerpen

    Antwerp, Belgium · Withdrawn

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • H.U.B.

    Brussels, Belgium · Active not recruiting

  • Antwerp University Hospital

    Edegem, Belgium · Recruiting

  • Centre Hospitalier Universitaire Sart Tilman

    Liège, Belgium · Active not recruiting

  • AZ Klina

    Brasschaat, Antwerp, Belgium · Recruiting

  • AZ Rivierenland

    Rumst, Antwerp, Belgium · Active not recruiting

  • Ghent University Hospital

    Ghent, East Flanders, Belgium · Active not recruiting

  • VITAZ

    Sint-Niklaas, East-Flanders, Belgium · Recruiting

  • University Hospital Leuven

    Leuven, Flemish Brabant, Belgium · Recruiting

  • Grand Hôpital de Charleroi

    Charleroi, Hainaut, Belgium · Active not recruiting

  • UMC Groningen

    Groningen, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • Rijnstate

    Arnhem, Gelderland, Netherlands · Recruiting

  • Maastricht UMC+

    Maastricht, Limburg, Netherlands · Recruiting

  • Maxima Medisch Centrum

    Eindhoven, North Brabant, Netherlands · Active not recruiting

  • Amsterdam UMC

    Amsterdam, North Holland, Netherlands · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.